Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta blockers after myocardial infarction--aspects on study design based on current knowledge.

A Vedin, C Wilhelmsson

    Acta Medica Scandinavica. Supplementum
    |January 1, 1981
    PubMed
    Summary

    Beta-blockers like alprenolol and practolol show promise in reducing sudden cardiac death after myocardial infarction. However, further research is needed to determine optimal dosing and patient selection for long-term benefits.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Resource prioritization in a learning system for health care.

    The American journal of gastroenterology·2001
    Same author

    Serotonin 5-HT2A receptor binding in platelets from patients with Alzheimer's disease or vascular dementia.

    International psychogeriatrics·2001
    Same author

    Low serum sodium concentrations during treatment with citalopram in elderly patients: relationship to serum citalopram levels and to platelet serotonin 5-HT2A receptor status.

    Journal of clinical psychopharmacology·2000
    Same author

    Who determines the research agenda?--II.

    Scandinavian cardiovascular journal : SCJ·2000
    Same author

    Clarificatioin of AstraZeneca's R&D strategies.

    Science (New York, N.Y.)·2000
    Same author

    Regulation of circulating leptin in humans.

    Endocrine·1997

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Background:

    • Beta-blocker trials are categorized into retrospective, prospective non-conclusive, and prospective conclusive studies.
    • Retrospective studies have limitations and offer only supportive evidence.
    • Four prospective studies (three with alprenolol, one with practolol) have yielded positive results.

    Purpose of the Study:

    • To evaluate the efficacy of beta-blockers in reducing long-term mortality from sudden cardiac death post-myocardial infarction.
    • To identify limitations and unanswered questions in existing beta-blocker research.
    • To propose directions for future research to improve treatment strategies.

    Main Methods:

    • Analysis of existing beta-blocker trial data, categorized by study design.

    Related Experiment Videos

  • Critical review of published studies, noting methodological weaknesses and limitations.
  • Identification of knowledge gaps regarding dosage, plasma levels, and long-term effects.

    • Main Results:

    • Alprenolol and practolol appear to reduce long-term mortality due to sudden death from ischemic heart disease after myocardial infarction.
    • Existing studies are criticized for various grounds, including short observation periods (max 2 years).
    • The precise identification of patients who would benefit most from beta-blocker treatment remains challenging.

    Conclusions:

    • Beta-blockers (alprenolol, practolol) may reduce mortality post-myocardial infarction, but current evidence has limitations.
    • Further research is needed to understand optimal dosing, plasma levels, and long-term efficacy.
    • Future studies should utilize large, representative patient groups, stratified designs, and beta-blockers with distinct ancillary properties.